Castle Biosciences News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

20.05.21	Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors (Businesswire)
19.05.21	Castle Biosciences to Participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit (Businesswire)
11.05.21	Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences’ Board of Directors (Businesswire)
10.05.21	Castle Biosciences Announces First Quarter 2021 Results (Businesswire)
10.05.21	Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermatitis and Related Conditions (Businesswire)
06.05.21	Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program (Businesswire)
05.05.21	New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test (Businesswire)
04.05.21	Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S. (Businesswire)
30.04.21	Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness Month (Businesswire)
27.04.21	Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory (Businesswire)
26.04.21	Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021 (Businesswire)
23.04.21	Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population (Businesswire)
22.04.21	Castle Biosciences Presents Data at the Dermatology Nurses’ Association 2021 Annual Convention (Businesswire)
16.04.21	Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress (Businesswire)
14.04.21	Largest, Independent, Prospective Study Demonstrates Utility of DecisionDx®-Melanoma for Prediction of Outcomes in Patients With Cutaneous Melanoma Referred for Sentinel Node Biopsy (Businesswire)
13.04.21	Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma (Businesswire)
01.04.21	Castle Biosciences Collaborates with the Melanoma Research Foundation for "Ask the Expert” Live Webinar Series with Melanoma Experts (Businesswire)
29.03.21	Castle Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference (Businesswire)
25.03.21	Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions (Businesswire)
08.03.21	Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results (Businesswire)
22.02.21	Castle Biosciences to Release Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Monday, March 8, 2021 (Businesswire)
20.01.21	Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference (Businesswire)
13.01.21	Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results (Businesswire)
04.01.21	Castle Biosciences to Present at the 23rd Annual Needham Virtual Growth Conference (Businesswire)
22.12.20	Castle Biosciences Announces Early Repayment of Debt (Businesswire)
18.12.20	Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares (Businesswire)
16.12.20	Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock (Businesswire)
14.12.20	Castle Biosciences Announces Commencement of Proposed Public Offering of Common Stock (Businesswire)
04.12.20	Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma (Businesswire)
23.11.20	Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference (Businesswire)
17.11.20	Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pigmented Lesions (Businesswire)
12.11.20	Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx® DiffDx™-Melanoma Tests at American Society of Dermatopathology (ASDP) 57th Virtual Annual Meeting (Businesswire)
09.11.20	Castle Biosciences Announces Third Quarter 2020 Results (Businesswire)
02.11.20	Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma (Businesswire)
29.10.20	Castle Biosciences to Present Data at the American Society of Dermatopathology (ASDP) 57th Virtual Annual Meeting (Businesswire)
26.10.20	Castle Biosciences to Release Third Quarter 2020 Financial Results and Host Conference Call on Monday, November 9, 2020 (Businesswire)
21.10.20	Castle Biosciences to Hold Webcast for Investors Highlighting Commercial Launch of ConfirmDx®-Melanoma (Businesswire)
16.10.20	Castle Biosciences Presents Data on DecisionDx-Melanoma at the Virtual European Association of Dermato-Oncology (EADO) Congress (Businesswire)
12.10.20	Castle Biosciences Presents Data at the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting (Businesswire)
08.10.20	Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma (Businesswire)
06.10.20	Castle Biosciences to Present Data at the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting (Businesswire)
04.09.20	Castle Biosciences to Present at the Baird 2020 Global Healthcare Conference (Businesswire)
02.09.20	Castle Biosciences Announces Commercial Launch of DecisionDx-SCC (Businesswire)
01.09.20	Castle Biosciences Announces Leadership Promotions and New Medical Director (Businesswire)
26.08.20	Castle Biosciences to Hold Webcast Highlighting Commercial Launch of DecisionDx-SCC (Businesswire)
10.08.20	Castle Biosciences Announces Second Quarter 2020 Results (Businesswire)
05.08.20	Castle Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference (Businesswire)
27.07.20	Castle Biosciences to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020 (Businesswire)
15.07.20	Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma (Businesswire)
09.07.20	Second Systematic Review and Meta-Analysis Published Demonstrating DecisionDx-Melanoma as Independent Predictor of Recurrence, Distant Metastasis and Overall Survival in Cutaneous Melanoma (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	137.35	1.40 %	K V
Sonova Hldg	297.30	1.29 %	K V
Logitech Intl	74.86	1.22 %	K V
Nestle	75.22	1.02 %	K V
Alcon	76.32	0.95 %	K V
UBS Group	28.17	-0.67 %	K V
Swiss Re	131.95	-0.68 %	K V
Geberit	533.80	-0.78 %	K V
Lonza Grp	541.40	-0.81 %	K V
Kuehne+Nagel Int	202.60	-1.65 %	K V